Small Pharma Implements Costs Cut: New R&D Strategy And Management Team Change
Portfolio Pulse from Lara Goldstein
Small Pharma Inc. (OTCQB:DMTTF) has announced a cost-cutting strategy, changes in its management team, and an update to its R&D strategy. The company aims to expedite the clinical program of its novel deuterated DMT compound SPL028, which is currently in Phase 1 study. Preliminary findings show that SPL028 produces a psychedelic experience of less than one hour and is well-tolerated. The company's co-founder, Peter Rands, has left his positions, and the company is also reducing its headcount by 30%. Topline data from the ongoing Phase 1 study is expected in Q4 2023.
July 05, 2023 | 8:46 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Small Pharma Inc. is implementing a cost-cutting strategy and changes in its management team, which could impact investor confidence. The company's focus on its novel compound SPL028 could potentially lead to future growth.
The cost-cutting strategy and management changes could lead to short-term uncertainty among investors, potentially impacting the stock price. However, the company's focus on its novel compound SPL028, if successful, could lead to future growth and positively impact the stock price in the long term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100